Publications by authors named "Jose Elias Miziara"
Article Synopsis
- LCINS accounts for 20% of lung cancer cases, with the study focusing on the molecular profile of driver genes in Brazilian patients who never smoked.
- The investigation involved studying mutational and gene fusion status in 119 lung adenocarcinomas using advanced sequencing techniques, alongside genetic ancestry analysis.
- Results showed high mutation rates in genes like EGFR and TP53, with significant findings on ancestry influencing mutation patterns, and highlighted that a large percentage of patients have potential targets for effective treatment.
Disruptive and Truncating TP53 Mutations Are Associated with African-Ancestry and Worse Prognosis in Brazilian Patients with Lung Adenocarcinoma.
Pathobiology
November 2023
Introduction: TP53 is the most frequently mutated gene in lung tumors, but its prognostic role in admixed populations, such as Brazilians, remains unclear. In this study, we aimed to evaluate the frequency and clinicopathological impact of TP53 mutations in non-small cell lung cancer (NSCLC) patients in Brazil.
Methods: We analyzed 446 NSCLC patients from Barretos Cancer Hospital.
Introduction: Lung cancer is the deadliest cancer worldwide and in Brazil. Despite strong evidence, lung cancer screening by low-dose computed tomography (LDCT) in high-risk individuals is far from a reality in many countries, particularly in Brazil. Brazil has a universal public health system marked with important inequalities.
View Article and Find Full Text PDFMutational profile of Brazilian lung adenocarcinoma unveils association of EGFR mutations with high Asian ancestry and independent prognostic role of KRAS mutations.
Sci Rep
March 2019
Lung cancer is the deadliest cancer worldwide. The mutational frequency of EGFR and KRAS genes in lung adenocarcinoma varies worldwide per ethnicity and smoking. The impact of EGFR and KRAS mutations in Brazilian lung cancer remains poorly explored.
View Article and Find Full Text PDFArticle Synopsis
- EGF and EGFR are significant in lung cancer development, and a specific SNP in the EGF promoter (EGF+61 A>G) has been linked to cancer risk, but its role in lung cancer remains unclear.
- A study involving 669 lung cancer patients and 1104 controls in Brazil found no significant association between the EGF+61 A>G SNP and lung cancer risk, despite recognizing tobacco use and age as significant factors.
- The research determined that genotype frequencies in patients and controls did not show meaningful differences, concluding that EGF+61 A>G SNP is not a risk factor for lung cancer in the Brazilian population.
Background: ALK-rearranged lung cancers exhibit specific pathologic and clinical features and are responsive to anti-ALK therapies. Therefore, the detection of ALK-rearrangement is fundamental for personalized lung cancer therapy. Recently, new molecular techniques, such as NanoString nCounter, have been developed to detect ALK fusions with more accuracy and sensitivity.
View Article and Find Full Text PDF